What's New in Diabetic Neuropathy?
What's New in Diabetic Neuropathy?
What's New in Diabetic Neuropathy?
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Remember<br />
• This is chronic disease, and the chronic effects of drug<br />
therapies are unknown. Trials are short.<br />
• No s<strong>in</strong>gle medication has a robust effect on pa<strong>in</strong><br />
• Placebo up to 50% effective<br />
• Effectiveness poor <strong>in</strong> pa<strong>in</strong> (11%) & QOL<br />
• Side effects high<br />
• Cost is high<br />
• Pharmacologic treatment targets pa<strong>in</strong>, not numbness<br />
• Estimated numbers needed to treat (NNT) but not<br />
numbers needed to harm (NNH) available<br />
Presented by IHS Division of Diabetes<br />
36
Change language